- Home
- VANI vs ACHV Comparison
VANI vs ACHV Comparison
Compare VANI & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VANI
- ACHV
- Stock Information
- Founded
- VANI 1998
- ACHV N/A
- Country
- VANI United States
- ACHV Canada
- Employees
- VANI N/A
- ACHV N/A
- Industry
- VANI Biotechnology: Electromedical & Electrotherapeutic Apparatus
- ACHV Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- VANI Health Care
- ACHV Health Care
- Exchange
- VANI Nasdaq
- ACHV Nasdaq
- Market Cap
- VANI 68.1M
- ACHV 72.5M
- IPO Year
- VANI 2014
- ACHV N/A
- Fundamental
- Price
- VANI $1.26
- ACHV $3.58
- Analyst Decision
- VANI Strong Buy
- ACHV Strong Buy
- Analyst Count
- VANI 1
- ACHV 3
- Target Price
- VANI $4.00
- ACHV $14.33
- AVG Volume (30 Days)
- VANI 66.4K
- ACHV 234.9K
- Earning Date
- VANI 05-13-2025
- ACHV 05-13-2025
- Dividend Yield
- VANI N/A
- ACHV N/A
- EPS Growth
- VANI N/A
- ACHV N/A
- EPS
- VANI N/A
- ACHV N/A
- Revenue
- VANI N/A
- ACHV N/A
- Revenue This Year
- VANI N/A
- ACHV N/A
- Revenue Next Year
- VANI N/A
- ACHV N/A
- P/E Ratio
- VANI N/A
- ACHV N/A
- Revenue Growth
- VANI N/A
- ACHV N/A
- 52 Week Low
- VANI $0.91
- ACHV $1.84
- 52 Week High
- VANI $2.09
- ACHV $5.58
- Technical
- Relative Strength Index (RSI)
- VANI 77.37
- ACHV 69.97
- Support Level
- VANI $1.13
- ACHV $2.89
- Resistance Level
- VANI $1.16
- ACHV $3.32
- Average True Range (ATR)
- VANI 0.05
- ACHV 0.25
- MACD
- VANI 0.02
- ACHV 0.06
- Stochastic Oscillator
- VANI 92.86
- ACHV 95.12
About VANI Vivani Medical Inc. (DE)
Vivani Medical Inc is a preclinical-stage biopharmaceutical company. The company develops miniaturized, subdermal implants utilizing its proprietary NanoPortal technology to enable long-term, near-constant-rate delivery of a broad range of medicines to treat chronic diseases. It has two reporting segments, the Biopharm Division and the Neuromodulation Division. The Biopharm Division includes activities from NPM and Vivani Medical Australia Pty Ltd, and the Neurostimulation Division includes activities from Cortigent and its subsidiary in Switzerland.
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.